SAR445710

P1, N=45, Terminated, Kadmon, a Sanofi Company | Trial completion date: Jul 2026 --> Dec 2023 | Recruiting --> Terminated | Trial primary completion date: Sep 2025 --> Dec 2023; Sponsor's decision.

P1, N=51, Recruiting, Kadmon, a Sanofi Company | N=80 --> 51

Enrolment continues in the QW schedule. Conclusions SAR445710 demonstrated a manageable toxicity profile with on-mechanism pharmacodynamics consistent with IL-15 agonism.

P1, N=80, Recruiting, Kadmon, a Sanofi Company | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Jul 2025 --> Feb 2026

Our data strongly points to a T cell memory response within the tumor draining lymph node as a possible driver of protection from systemic cancer recurrence, laying the groundwork for a new therapeutic strategy aimed at establishing CD8 immunosurveillance for protection from cancer recurrence.

We hypothesized that targeting the immune repertoire of the tumor draining lymph node (TDLN) with a memory inducing IL-15-PDL1 bispecific antibody (KD033) would establish immunosurveillance and decrease metastatic recurrence... Our data suggests that an Il-15/anti-PD1 neoadjuvant treatment strategy maintains an optimal response to metastatic recurrence. Promoting T-cell memory in the TDLN through IL-15-based immunomodulation may increase immunosurveillance and thus improve overall survival providing a rationale for an upcoming neoadjuvant clinical trial.

Kadmon has established a bi-functional cytokine fusion antibody platform, including KD033 (anti-PD-L1/IL15) and KD050 (anti-PD-1/IL15) fusion antibody, to extend the IL15 serum half-life and direct its action to tumors and/or T cells in the tumor microenvironment (TME). Legal entity responsible for the study Kadmon Corporation LLC. Funding Kadmon Corporation LLC.

One patient (adenoid cystic carcinoma) in C1 was shown to have stable disease for more than 6 months and one patient (metastatic gastric adenocarcinoma) in C3 was shown to have stable disease for more than 4 months. Conclusions To date, KD033 has been well tolerated in all subjects with on-mechanism pharmacodynamics consistent with IL-15 agonism.

Conclusions Increased in vitro IFNγ secretion from KD033-treated macrophages correlated with increased CD68/IFNγ double positive cell infiltrations in PD-L1 negative MC38 tumors from KD033-treated human PD-1/PD-L1 transgenic mice as evaluated by IHC. We hypothesized that our anti-PD-L1/IL15 KD033 induces anti-tumor immunity in PD-L1 negative tumors by activating PD-L1-expressing immune cells such as macrophages in the tumor microenvironment.

These showed that the efficacy of anti-PD-L1-IL-15 fusion protein is not limited to PD-L1 tumor expression as KD033 was efficacious in both PD-L1 positive and negative tumors.

These results showed that the efficacy of anti-PD-L1-IL-15 fusion protein is not limited to PD-L1 tumor expression as KD033 was efficacious in both PD-L1 positive and negative tumors . Mol Cancer Ther February 1 2021 (20) (2) 347-356; DOI: 10.1158/1535-7163.MCT-20-0457

KD033 has been well tolerated early in dose escalation with on-mechanism pharmacodynamics consistent with IL-15 agonism.

An antibody-based immunocytokine fusion such as Kadmon lead candidate KD033 (anti-PDL1/IL15) and Roche anti-PD1/CEA/FAP-IL2v can extend the half-life of cytokine and reduce systemic toxicities...In addition, anti-mPD1/mSD15 showed better efficacy than either the mIL15 and anti-mPD1 alone or the combination of anti-mPD1 plus mIL15 in vitro and in vivo. Together these preclinical data have confirmed that PD1-IL15 could be a promising next generation IL-15 fusion for cancer immunotherapy.

srKD033 inhibited tumor growth inhibition and demonstrated evidence of epitope spreading. Broad activation of innate and adaptive immune responses in tumors was observed. These observations strongly support KD033 clinical development.

KD033 administration increases CD8+ T and NK cells, consistent with IL-15 pharmacodynamics. In addition, analysis of peripheral blood from KD033 surrogate best and non-responder mice demonstrated increases in different immune populations, which can facilitate their use as in-treatment biomarkers of KD033 activity in tumors. Importantly, KD033 administration resulted in increases in rare cytotoxic cells such as NKT and gamma delta T cells in peripheral blood which may contribute to its anti-tumor activity and immunity.Legal entity responsible for the study: Kadmon Corporation LLC.